Financial Performance - The company's revenue for Q1 2025 was ¥608,114,432.73, a decrease of 4.15% compared to ¥634,423,439.84 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥10,771,559.48, representing a decline of 398.84% from a profit of ¥3,604,469.38 in the previous year[5] - The basic and diluted earnings per share were both -¥0.0122, a decrease of 397.56% from ¥0.0041 in the previous year[5] - The net profit for the current period was a loss of ¥13,694,996.56, compared to a profit of ¥491,602.42 in the previous period[18] - Total operating revenue for the current period was ¥608,114,432.73, a decrease of 4.9% from ¥634,423,439.84 in the previous period[17] - Total operating costs decreased to ¥618,458,434.15, down 3.2% from ¥638,885,020.11 in the previous period[17] Cash Flow - The net cash flow from operating activities improved by 64.93%, with a net outflow of ¥115,498,516.08 compared to ¥329,363,302.09 in the same period last year[5] - Operating cash inflow for the current period was $1,028,126,246.44, an increase of 14.7% compared to $896,017,087.68 in the previous period[20] - Total cash outflow from operating activities was $1,143,624,762.52, a decrease of 6.7% from $1,225,380,389.77 in the previous period[20] - Cash inflow from investment activities totaled $3,022,163.73, down from $8,280,003.27 in the previous period[20] - Net cash flow from investment activities was $2,021,441.72, a decrease of 60% compared to $5,059,856.24 in the previous period[20] - Cash inflow from financing activities was $53,000,000.00, down from $131,918,000.00 in the previous period[21] - Net cash flow from financing activities was $47,797,968.44, a decrease of 62% compared to $126,110,289.17 in the previous period[21] - The ending cash and cash equivalents balance was $459,153,640.58, down from $605,354,784.33 in the previous period[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,028,781,224.55, down 2.37% from ¥3,102,263,464.06 at the end of the previous year[5] - Total liabilities decreased to ¥1,166,163,387.67, down 6.6% from ¥1,248,147,093.08 in the previous period[15] - The total current assets decreased from CNY 2,449.49 million to CNY 2,357.20 million, a decline of about 3.76%[13] - The total non-current assets slightly decreased from CNY 1,020.73 million to CNY 1,018.73 million, a reduction of approximately 0.20%[13] Shareholder Information - The total number of common shareholders at the end of the reporting period is 70,774[9] - The top three shareholders hold the following percentages: Tong Wenwei 7.37%, Shi Yazhiyu 6.46%, and Zhong Feipeng 6.24%[9] - The company has a total of 189,768,085 shares subject to restrictions at the end of the reporting period[11] Other Comprehensive Income - The company reported a significant increase in other comprehensive income, which rose by 279.85% to ¥14,265,021.10 due to fair value changes in equity investments[7] - Other comprehensive income after tax for the current period was ¥22,196,462.46, significantly higher than ¥7,218,154.98 in the previous period[18] - The total comprehensive income for the current period was ¥8,501,465.90, compared to ¥7,709,757.40 in the previous period, indicating an increase of 10.2%[18] Investment and Development - Investment income decreased by 790.87%, resulting in a loss of ¥1,152,633.26 compared to a gain of ¥166,838.16 in the previous year[7] - The company recorded a 72.13% decline in non-operating income, which fell to ¥5,335.31 from ¥19,141.41 in the same period last year[7] - The company has not disclosed any new product developments or market expansion strategies in the current report[1] - The company has not disclosed any new product or technology developments during this reporting period[12] - There are no significant mergers or acquisitions reported in this quarter[12] - The company reported a significant increase in research and development expenses, totaling ¥24,366,751.03, down from ¥27,427,342.75 in the previous period, reflecting a decrease of 11.3%[17]

■■■■■300310■■■■2025■■■■■■■■■6.08■■■■■■■4.15%■■■■1077.16■■■■■■■■■■360.45■■■ ...

1. 公司提供予本所之文件中的所有签署、盖章及印章均是真实的，所有作为正本 提交给本所的文件均是真实、准确、完整的； 广州市天河区珠江新城珠江西路 21 号 粤海金融中心 28 层 邮编：510627 电话：(86-20) 2805-9088 传真：(86-20) 2805-9099 北京市君合（广州）律师事务所 关于宜通世纪科技股份有限公司 2024 年度股东大会的法律意见 致：宜通世纪科技股份有限公司 北京市君合（广州）律师事务所（以下简称"本所"）接受宜通世纪科技股份有限 公司（以下简称"公司"）的委托，指派本所经办律师出席了公司于 2025 年 4 月 22 日 在广州市天河区科韵路 16 号广州信息港 A 栋 12 楼 1 号会议室召开的 2024 年度股东大 会（以下简称"本次股东大会"）的现场会议。现根据《中华人民共和国公司法》《中华 人民共和国证券法》《上市公司股东会规则》《深圳证券交易所创业板股票上市规则》等 中华人民共和国现行法律、法规和规范性文件（仅为本法律意见之目的，未包括中华人 民共和国香港特别行政区、澳门特别行政区及台湾地区的法律法规，以下简称"法律、 法规"）以及《宜通世纪科技股 ...

证券代码：300310 证券简称：宜通世纪 公告编号：2025-016 宜通世纪科技股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未出现涉及变更前次股东大会决议的情形； 3、本次股东大会采取现场投票、网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议的召开情况 5、主持人：公司董事长钟飞鹏先生。 6、本次会议的召集、召开与表决程序符合国家有关法律、法规、部门规章、 规范性文件和《公司章程》的规定。 证券代码：300310 证券简称：宜通世纪 公告编号：2025-016 1、召集人：公司董事会 2、会议召开时间： （1）现场会议时间：2025 年 4 月 22 日 14:30 （2）网络投票时间：2025 年 4 月 22 日。其中，通过深圳证券交易所交易 系统进行网络投票的具体时间：2025 年 4 月 22 日的交易时间，即：9:15—9:25， 9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的具 ...

Group 1 - Company Instech reported a net profit of 177 million yuan for 2024, a year-on-year increase of 28.15%, with a proposed cash dividend of 1.20 yuan per 10 shares [1] - Instech achieved an operating revenue of 1.185 billion yuan in 2024, representing a year-on-year growth of 24.45% [1] - The company specializes in the research, production, and sales of rare earth permanent magnet materials and applications [2] Group 2 - Company Junda reported a net loss of 106 million yuan for Q1 2025, transitioning from profit to loss, with a year-on-year revenue decline of 49.52% [3] - Junda's operating revenue for Q1 2025 was 1.875 billion yuan [3] - The company focuses on the research, production, and sales of photovoltaic cell products [4] Group 3 - Company Annada reported a net loss of 10.26 million yuan for Q1 2025, with a year-on-year revenue increase of 1.44% [5] - Annada's operating revenue for Q1 2025 was 473 million yuan [5] - The company specializes in titanium dioxide and iron phosphate products [6] Group 4 - Company Jiuzhou Pharmaceutical reported a net profit of 250 million yuan for Q1 2025, a year-on-year increase of 5.68% [7] - Jiuzhou's operating revenue for Q1 2025 was 1.49 billion yuan, reflecting a year-on-year growth of 0.98% [7] - The company provides custom research and production services for pharmaceutical companies and research institutions [8] Group 5 - Company Yitong Century won a 1.48 billion yuan contract for a 5G comprehensive maintenance project with Guangdong Unicom [9] - The project will enhance the company's business volume and expansion in Guangdong [9] - Yitong Century specializes in communication network technology services and solutions [10] Group 6 - Company Rijiu Optoelectronics reported a net profit of 67.47 million yuan for 2024, a year-on-year increase of 506.9%, with a proposed cash dividend of 2.00 yuan per 10 shares [10] - Rijiu's operating revenue for 2024 was 583 million yuan, representing a year-on-year growth of 22% [10] - The company focuses on the research, production, and sales of touch display application materials [11] Group 7 - Company Ruotong reported a net profit of 95.98 million yuan for 2024, a year-on-year increase of 0.91%, with a proposed cash dividend of 2.00 yuan per 10 shares [12] - Ruotong's operating revenue for 2024 was 408 million yuan, reflecting a year-on-year growth of 7.54% [12] - The company specializes in drilling and completion equipment for oil and gas [13] Group 8 - Company Shuangxiang reported a net profit of 472 million yuan for 2024, a year-on-year increase of 754.84%, with a proposed cash dividend of 1.50 yuan per 10 shares [14] - Shuangxiang's operating revenue for 2024 was 2.29 billion yuan, representing a year-on-year growth of 51.55% [14] - The company focuses on synthetic leather and optical-grade PMMA products [15] Group 9 - Company Xinfang Pharmaceutical reported a net profit of 101 million yuan for 2024, a year-on-year decrease of 64.70%, with a proposed cash dividend of 0.30 yuan per 10 shares [16] - Xinfang's operating revenue for 2024 was 6.032 billion yuan, reflecting a year-on-year decline of 6.63% [16] - The company is involved in medical services, pharmaceutical distribution, and manufacturing [17] Group 10 - Company Dongxing Medical reported a net profit of 97.42 million yuan for 2024, a year-on-year increase of 0.21%, with a proposed cash dividend of 6.00 yuan per 10 shares [18] - Dongxing's operating revenue for 2024 was 435 million yuan, reflecting a year-on-year growth of 0.40% [18] - The company specializes in surgical medical devices [19] Group 11 - Company Wuzhou Special Paper reported a net profit of 64.68 million yuan for Q1 2025, a year-on-year decrease of 51.56%, with an operating revenue of 1.989 billion yuan [20] - Wuzhou's operating revenue for Q1 2025 increased by 15.21% [20] - The company focuses on the research, production, and sales of mechanism paper and pulp [21] Group 12 - Company Jinrui Mining expects a net profit of 15.28 million yuan for Q1 2025, a year-on-year increase of 617.40% [22] - The company specializes in the production and sales of strontium salt products [23] Group 13 - Company Youyan New Materials expects a net profit of 60 million to 75 million yuan for Q1 2025, a year-on-year increase of 13076% to 16370% [24] - The company focuses on electronic films, precious metal materials, and rare earth materials [25] Group 14 - Company Guoli expects a net profit of 11 million to 13 million yuan for Q1 2025, a year-on-year increase of 164.38% to 212.45% [26] - The company specializes in urban infrastructure design, construction, and investment [27] Group 15 - Company Shenzhen Airport reported a passenger throughput of 5.5422 million in March, a year-on-year increase of 8.70% [28] - The airport's cargo throughput was 171,900 tons, reflecting a year-on-year growth of 14.51% [28] - The company is involved in aviation and related non-aviation businesses [29] Group 16 - Company Shenghui Integration reported an order balance of 2.117 billion yuan as of March 31, 2025, a year-on-year increase of 11.89% [30] - The company provides cleanroom engineering and electromechanical engineering services [31] Group 17 - Company Chengyi Pharmaceutical received a drug registration certificate for Mercaptopurine tablets [32] - The drug is applicable for various diseases including choriocarcinoma and acute lymphoblastic leukemia [32] Group 18 - Company Enhua Pharmaceutical initiated Phase I clinical trials for NH280105 capsules, targeting Alzheimer's disease [33] - The trial aims to assess the safety and pharmacokinetics of the drug [33] Group 19 - Company Lingang Steel proposed a share buyback of 50 million to 100 million yuan [34] - The company specializes in the production and development of metallurgical products [35] Group 20 - Company Fujia plans to repurchase shares worth 15 million to 30 million yuan [36] - The company focuses on smart cleaning appliances and key components [37] Group 21 - Company Mould Technology received a project designation letter for exterior parts from a luxury car client, with an estimated total sales of 2.07 billion yuan [38] - The project is expected to start mass production in April 2027 [38] Group 22 - Company Longxin General expects a net profit of 4.55 billion to 5.30 billion yuan for Q1 2025, a year-on-year increase of 76.65% to 105.77% [39] - The company specializes in motorcycles, engines, and general machinery products [40] Group 23 - Company Dongfang Securities reported a net profit of 1.436 billion yuan for Q1 2025, a year-on-year increase of 62.08% [41] - The company focuses on investment management and securities trading [42] Group 24 - Company Yalian Machinery plans to use up to 800 million yuan of idle funds for low-risk financial products [43] - The company specializes in the production of engineered wood production lines and equipment [44] Group 25 - Company Guanghua Technology reported a net loss of 205 million yuan for 2024, with total revenue of 2.589 billion yuan [45] - The company focuses on PCB chemicals and lithium battery materials [46] Group 26 - Company Boya Biotechnology plans to publicly transfer 80% of its subsidiary's equity for 213 million yuan [47] - The transaction aims to optimize resource allocation focusing on blood products [48] Group 27 - Company Darui Electronics plans to repurchase shares worth 30 million to 50 million yuan [49] - The company specializes in customized components and automation equipment [50] Group 28 - Company Hongying Intelligent plans to repurchase shares worth 30 million to 40 million yuan [51] - The company focuses on smart control products and assemblies [52] Group 29 - Company Guangku Technology announced a change in the upper shareholding structure of its controlling shareholder [53] - The operational activities of the company will not be materially affected [54] Group 30 - Company Dingjie Smart's application for convertible bond issuance has been accepted by the Shenzhen Stock Exchange [55] - The company provides digital and intelligent solutions for various industries [56]

宜通世纪（300310）公告，公司成为2025-2026年广东联通综合代维5G采购项目的中标单位。项目服务 内容包括综合代维、政企装拆移机、修理等8个专业维护服务，以及广东联通线路及配套更新改造服 务。中标规模合计为1.48亿元(不含税)，其中非承建区标段6中标占比14.00%，中标金额为6970万元；承 建区标段5中标占比15.61%，中标金额为7800万元。此次中选符合公司的业务发展规划，若能签订正式 合同并顺利实施，将对公司未来在广东的业务量增长和进一步拓展有积极意义。 ...

证券代码：300310 证券简称：宜通世纪 公告编号：2025-015 宜通世纪科技股份有限公司 关于项目中标的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宜通世纪科技股份有限公司（以下简称"公司"）于 2025 年 4 月 8 日在巨潮 资讯网（www.cninfo.com.cn）披露了《关于中标候选人公示的提示性公告》（公 告编号：2025-014），公司成为 2025-2026 年广东联通综合代维 5G 采购项目非承 建区标段 6、承建区标段 5 的中标候选人。 近日，公司收到相关招标机构发出的中标通知书，获悉公司成为上述项目的 中标单位，现将具体情况公告如下： 一、公司中标项目的基本情况 1、项目名称：2025-2026 年广东联通综合代维 5G（承建/非承建区）采购项 目 2、项目服务内容：为广东联通提供综合代维、政企装拆移机、修理、技改 服务，包含线路（含干线）维护、无线基站/室分维护、政企用户维护、公众用 户接入维护（上联的接入间、线缆、设备（含两级分光器）和联通投资自建三化 上联设备线路）、机楼维护、防汛应急支援、政企装拆移机、修理 ...

答：您好，第四季度亏损金额较高，主要是公司计提资产减值准备， 其中天河鸿城物联网业务资产组计提商誉减值损失 3127 万元，这一减 值直接减少公司净利润。谢谢您的关注，请注意投资风险。 3.公司之后的盈利有什么增长点？ 答：你好，通信服务市场业务相对稳定，虽然目前行业比较低潮，但 通信网络总量是逐年增长的，而通信服务如工程建设、维护、优化等 是刚需，这为公司的稳健运营提供了基础。公司计划除了继续开拓传 统运营商市场提高市场占有率之外，还将加强与运营商联动，开辟政 企市场、行业应用 ICT 解决方案等业务获得增量；三是加强公司工业 物联网产品及航空产品的推广，力争形成新的增长点。从而提高公司 收入和利润水平。谢谢你的提问，请注意投资风险。 4.公司本期盈利水平如何？ 证 券 代 宜通世纪科技股份有限公司投资者活动记录表 编 | ： | | | 编 | | --- | --- | --- | --- | | | 证券简称：宜通世纪 □特定对象调研 | □分析师会议 | | | | | | 号 | | 投资者关系活动 | □媒体采访 | √业绩说明会 | ： | | | □新闻发布会 | □路演活动 | | | 类 ...

证券代码：300310 证券简称：宜通世纪 公告编号：2025-014 3、本项目框架合同执行期为自合同生效之日起 2 年。 近日，中华人民共和国工业和信息化部通信工程建设项目招标投标管理信息 平台（https://txzbgl.miit.gov.cn/#/gateway）发布了《2025-2026 年广东联通综合代 维 5G（承建/非承建区）采购项目中标候选人公示》，宜通世纪科技股份有限公 司（以下简称"公司"）中标 2 个标段，整个服务周期中标规模合计 14,770 万元 （不含税）。现对相关情况公告如下： 一、中标项目的基本情况 1、项目名称：2025-2026 年广东联通综合代维 5G（承建/非承建区）采购项 目 2、项目服务内容：为广东联通提供综合代维、政企装拆移机、修理、技改 服务，包含线路（含干线）维护、无线基站/室分维护、政企用户维护、公众用 户接入维护（上联的接入间、线缆、设备（含两级分光器）和联通投资自建三化 上联设备线路）、机楼维护、防汛应急支援、政企装拆移机、修理 8 个专业维护 服务，以及广东联通线路及配套更新改造服务，对现网技术改造、更新改造。 宜通世纪科技股份有限公司 关于中标候 ...

Financial Performance - The company reported a basic earnings per share of -0.0300 yuan for 2024, a decrease of 160% compared to 0.0500 yuan in 2023 [1] - The net profit for 2024 was -0.3 billion yuan, representing a decline of 162.5% from 0.48 billion yuan in 2023 [1] - The return on equity (ROE) for 2024 was -1.62%, down 161.83% from 2.62% in 2023 [1] - Operating revenue decreased to 25.02 billion yuan in 2024, a drop of 5.94% from 26.6 billion yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 75.1022 million shares, accounting for 10.85% of the circulating shares, with a decrease of 6.0424 million shares compared to the previous period [1] - Notable changes in the top shareholders include the exit of Yu Qiaoying, Liu Jun, Xu Gang, and Qu Zhixin, while new entrants include Chen Xi, Hui Jianhai, Jiang Ping, and Du Yuhong [2] Dividend Policy - The company has announced no distribution or capital increase for the current period [1]